Page last updated: 2024-12-06

suritozole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID25431
CHEMBL ID278764
CHEBI ID177573
SCHEMBL ID121081
MeSH IDM0179659

Synonyms (30)

Synonym
CHEBI:177573
5-(3-luorophenyl)-2,4-dimethyl-1,2,4-triazole-3-thione
suritozole
mdl-26479
110623-33-1
suritozole (usan/inn)
D05980
2,4-dihydro-2,4-dimethyl-5-(3-fluorophenyl)-3h-1,2,4-triazole-3-thione
3-(m-fluorophenyl-1,4-dimethyl-delta(sup 2)-1,2,4-triazoline-5-thione
3h-1,2,4-triazole-3-thione, 2,4-dihydro-2,4-dimethyl-5-(3-fluorophenyl)-
suritozole [usan:inn]
mdl 26,479
3-(m-fluorophenyl)-1,4-dimethyl-delta(sup 2)-1,2,4-triazoline-5-thione
brn 6725971
3h-1,2,4-triazole-3-thione, 5-(3-fluorophenyl)-2,4-dihydro-2,4-dimethyl-
CHEMBL278764
5-(3-fluorophenyl)-2,4-dimethyl-1,2,4-triazole-3-thione
unii-3h7h68317x
3h7h68317x ,
SCHEMBL121081
suritozole [inn]
suritozole [who-dd]
suritozole [usan]
IWDUZEHNLHFBRZ-UHFFFAOYSA-N
DTXSID10149333
AKOS027201111
3-(3-fluorophenyl)-1,4-dimethyl-4,5-dihydro-1h-1,2,4-triazole-5-thione
Q7646369
EN300-253548
Z1509672221

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" MD pharmacokinetic parameters for doses from 30 to 120 mg were consistent with those observed following SD, thus indicating that SD pharmacokinetics are predictive of MD."( Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.
Bhargava, VO; Green, VI; Hutcheson, SJ; Miller, TD; Robbins, DK; Weir, SJ, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" In the second experiment, an early postinjury dosing procedure was followed."( Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury.
Hamm, RJ; O'Dell, DM, 1995
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID125702Concentration required to inhibit Monoamine oxidase A activity in rat brain using [14C]5-HT1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID126682Concentration required to inhibit Monoamine oxidase B in rat brain using [14C]phenylethylamine1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID175362Concentration required to inhibit [3H]- NE(norepinephrine) uptake in to rat cortical synaptosomes1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's7 (87.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.51 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]